Century Therapeutics Inc IPSC.OQ IPSC.O is expected to show a fall in quarterly revenue when it reports results on October 27 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Century Therapeutics Inc is for a loss of 34 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 1.1% in the last three months.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.38 | -0.38 | -0.38 | Met | -1.1 |
Mar. 31 2025 | 0.05 | 0.06 | 0.89 | Beat | 1,518.2 |
Dec. 31 2024 | -0.42 | -0.43 | Missed | -1.9 | |
Sep. 30 2024 | -0.44 | -0.45 | -0.37 | Beat | 17.4 |
Jun. 30 2024 | -0.47 | -0.46 | -0.38 | Beat | 17.6 |
Mar. 31 2024 | -0.52 | -0.50 | -0.45 | Beat | 10.4 |
Dec. 31 2023 | -0.46 | -0.55 | -0.65 | Missed | -17.3 |
Sep. 30 2023 | -0.52 | -0.51 | -0.55 | Missed | -7.3 |
This summary was machine generated October 24 at 12:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)